Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Jul162019
News

Shortened Exclusivity Could Save $31B

Alex Brill was recently quoted by Politico Pro about MGA’s recent “Gamesmanship and Other Barriers to Drug Competition” paper:

“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.

Tactics ranging from patent thickets to citizens’ petitions and authorized generics — identical drugs produced or authorized by the brand-name company — have been some of the most effective ways to delay market competition, Matrix’s Alex Brill writes.”

Read Here (Subscription Required)

July 16, 2019Category: News
Tags: big pharmahealth caremedicineprescription drugs

Post navigation

PreviousPrevious post:Conservative Thinkers Share Their Views for Biosimilars in a Post-ACA, BPCIA LandscapeNextNext post:MGA’s Alex Brill on CNBC’s Squawk Box
  • Analysis(27)
  • Books(2)
  • Events(13)
  • Interviews(33)
  • News(43)
  • Op-Eds(59)
  • Press Releases(2)
  • Testimony(18)
  • Almost-Speaker McCarthy
    November 23, 2020
  • Nursing Homes Prepare for Third COVID-19 Surge
    October 26, 2020
  • Impact of the Coronavirus Pandemic on Red, Blue, and Swing States
    October 20, 2020
  • Trump Roils Markets with Conflicting Statements on Pandemic Relief
    October 7, 2020

Website Design and Developed by DreamBig Creative